PCORI Funds Head-To-Head Drug Trial For Non-diabetic Neuropathy

Four drugs will be entered into an adaptive trial to find out which one is most effective and has the fewest side effects for treating cryptogenic sensory polyneuropathy, a designation for neuropathy for which no cause is found.